Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed. It was a busy week with lots of news, have a look and see you next week for another update.
Braxia Scientific Presents Positive Preliminary Findings from Phase II Clinical Trial of Psilocybin-Assisted Therapy for Depression
One of the industry’s early movers, Braxia (formerly Champignon), has finally come out with some solid news. They announced positive preliminary results from the first Health Canada Approved, Phase II, randomized clinical trial of multi-dose psilocybin-assisted therapy for Treatment-Resistant-Depression. The preliminary results were presented at the “From Research to Reality Conference” in Toronto, May 27-28, 2022.
Cybin Announces Roster of 28 Expert Faculty and Advisors for its EMBARK Psychedelic Facilitator Training Program
Cybin continues to develop its EMBARK program, announcing a roster of leaders and senior psychotherapy trainers from leading universities and psychedelic research organizations.
“For EMBARK, we have set out to build an extraordinary training program in psychedelic-assisted psychotherapy. We don’t think a single person holds all the answers. Instead, we have gathered together the wisdom of 28 of the world’s leading experts in psychedelic practice as teachers, supervisors, and advisors for our program…” said Dr. Alex Belser, Chief Clinical Officer at Cybin.
Awakn Life Sciences Initiates Follow-On Behavioral Study to Focus on Gambling Disorder
AWAKN has completed a successful pilot study for a range of behavioral addictions using ketamine and ketamine-assisted psychotherapy, and is moving forward with a larger study of 42 patients suffering from Gambling Disorders. The larger study will see participants undergo a memory reactivation procedure, which is designed to weaken the link between reward and addiction memories. The larger placebo-controlled study will be the first investigation globally to explore this technique to treat Gambling Disorder.
Novamind Reports Fiscal Q3 2022 Financial Results and Operating Highlights
Novamind reports record high quarterly revenue of $3,227,352 as it announces its Fiscal Q3 2022 Financial Results and Operating Highlights.
Novamind CEO, Yaron Conforti, commented, “Once again, we’re pleased to report record-high revenue this quarter. Growth was driven by our recent expansion to Arizona in addition to the continued progress of our Utah operations. With the anticipated shareholder approval of the acquisition of Novamind by Numinus in June, the Company is well-positioned to continue this record growth in pursuit of its mission to responsibly reintroduce psychedelic therapy to mental healthcare.”
Clearmind Medicine Granted Patent Approval for Psychedelic- Based Alcohol Substitute in India
Clearmind has been granted patent approval from the Office of the Controller-General of Patents, Designs and Trademarks in India. The patent refers to the company’s proprietary MEAI-based alcohol substitute patent family.
“Our innovation continues to gain global recognition, this time by the Indian patent office.” said Dr. Adi Zuloff- Shani, Clearmind’s Chief Executive Officer. “Clearmind is the sole owner of a family of patents concerning a synthetic substance as a replacement for alcohol.
Cybin Submits IND to FDA for Phase 1/2a Trial of CYB003
Doug Drysdale, Chief Executive Officer of Cybin. “This FDA submission is the next major step in the advancement of CYB003, and we continue to work tirelessly to bring this innovative therapeutic option to people as quickly as possible. We look forward to continuing to work with the FDA to initiate the Phase 1/2a trial in mid-2022.”
